Literature DB >> 6876744

Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits.

R Ginsburg, K Davis, M R Bristow, K McKennett, S R Kodsi, M E Billingham, J S Schroeder.   

Abstract

We tested the effects of the calcium antagonists lanthanum, diltiazem, and flunarizine on the development of atherosclerosis in rabbits fed a 2% cholesterol diet. The drugs were given orally and were well tolerated. In the cholesterol control animals, 52.2% of the thoracic aortic intimal surface was Sudan IV positive. This was reduced by 37% (p less than 0.05) with lanthanum, 37% (p less than 0.05) with diltiazem, and 34% (p less than or equal to 0.06) with flunarizine. In all cholesterol-fed animals, the intramural, but not subepicardial, coronary arteries were severely diseased. The extent and distribution of this disease were not altered by the various drug interventions. Thus, the calcium antagonists lanthanum, diltiazem, and flunarizine suppress atherogenesis of the rabbit aorta but have no effect on the extent or distribution of atherosclerosis in the intramural coronary arteries.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6876744

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  22 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

3.  Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits.

Authors:  Y Ohta; N Higuchi; S Emura; T Takashima; K Oogushi; H Kato; K Ohmori; T Sunaga
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

4.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

5.  Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?

Authors:  W Schneider; G Kober; P Roebruck; H Noack; M Alle; G Cieslinski; N Reifart; M Kaltenbach
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Effects of diltiazem on suppression and regression of experimental atherosclerosis.

Authors:  M Sugano; Y Nakashima; H Tasaki; M Takasugi; A Kuroiwa; O Koide
Journal:  Br J Exp Pathol       Date:  1988-08

7.  Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.

Authors:  D A Handley; R G Van Valen; M K Melden; R N Saunders
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

8.  Action of probucol in arteries from normal and hypercholesterolaemic rabbits.

Authors:  M Del Rio; T Chulia; E Ruiz; T Tejerina
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

9.  Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.

Authors:  M N el-Sanadiki; K S Cross; J J Murray; R W Schuman; E Mikat; R L McCann; P O Hagen
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

10.  Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade.

Authors:  A Daugherty; D L Rateri; G Schonfeld; B E Sobel
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.